FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
05 nov. 2018 13h00 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the FDA approved its IND to conduct a Phase 1b/2 trial of the safety and...
Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
09 oct. 2018 09h45 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety...
Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
21 août 2018 09h45 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement...
Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology’s Board of Directors
08 août 2018 11h30 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointments of two new members to the Board of Directors of Lixte: Yun Yen,...
LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
09 févr. 2018 09h45 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver,...
Lixte Biotechnology to Obtain High-Quality Tissue and Blood Samples from German University
11 janv. 2007 09h15 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, N.Y., Jan. 11, 2007 (PRIME NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. announced today that its wholly owned subsidiary, Lixte Biotechnology, Inc., entered into an agreement with...